Mylan Pharmaceuticals June 2 said that the Food and Drug Administration approved its venlafaxine hydrochloride (HCl) extended-release (ER) capsules, a generic version of Wyeth’s Effexor XR.
The drug is used to treat major depressive disorders and social anxiety disorder, Pittsburgh-based Mylan said. Mylan will be marketing the tablets in 37.5 mg, 75 mg, and 150 mg strengths and is launching the products under a settlement and licensing agreement with Wyeth, which now is part of Pfizer Inc. The pact allowed Mylan to start selling the drug as of June 2011
Venlafaxine HCl ER capsules had U.S. sales of approximately $2.3 ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.